IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023

• INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue.
• Data supports the potential for this next-generation CAR-T technology in previously “undruggable” solid- and liquid-tumor targets.

NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, has announced that preclinical data for its gamma-delta CAR-T technology, INB-300, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. The event will be held in Orlando, Florida, from April 14-19.

IN8bio’s non-signaling CAR (nsCAR) platform is based on the natural innate immune recognition of gamma-delta T cells. By using a CAR that lacks a CD3z signaling domain, IN8bio believes it has created a technology that enables these cells to differentiate between tumor and healthy tissue, even when both express the CAR-targeted antigen. IN8bio is not seeking to advance this construct into the clinic but the data to be presented includes a proof-of-concept study against the validated target of CD19. INB-300, a CD19 targeting nsCAR construct (ns19CAR), demonstrated the ability to distinguish between leukemic and healthy cells, killing 80% of the leukemia cells and only 5% of healthy B cells, both of which express CD19. Updated data, along with planned next steps for this nsCAR platform, will be presented at the AACR Annual Meeting.

“We are thrilled to present promising preclinical data from our next-generation CAR platform, which shows the potential of INB-300 to differentiate between cancerous and healthy tissue,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. “Our goal is to improve upon existing technologies with a targeted and potentially less toxic approach for patients who require more innovative therapies. We are encouraged by these results and look forward to further evaluating nsCAR programs in additional promising targets such as CD33 for acute myeloid leukemia (AML).”

AACR Presentation Details

Title: A non-signaling CAR for gamma-delta (γδ) T cells to preserve healthy tissues

Abstract Presentation Number: 1777

Session Title: CAR T-cell Therapy 1

Session Date and Time: Monday, April 17, 2023, 9:00am -12:30pm ET

About INB-300

INB-300, our non-signaling CAR (nsCAR) gamma-delta T cell platform, includes several preclinical product candidates combining our expertise in gamma-delta T cells and genetic engineering. These nsCAR constructs lack signaling domains in order to take advantage of the unique properties of gamma-delta T cells to differentiate between healthy and tumor tissues. IN8bio is advancing new nsCAR constructs against multiple targets to treat both solid and liquid tumors.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored Phase 2 clinical trial in newly diagnosed glioblastoma following IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: future positive results in clinical data relating to the INB-300 study or the nsCAR platform; the nsCAR platform’s potential to distinguish between tumor cells and healthy tissue; the timing and initiation of IN8bio’s clinical trials; INB-300’s ability to improve upon existing technologies; and IN8bio’s ability to evaluate nsCAR programs in additional promising targets such as CD3 for AML. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic as well as rising inflation and regulatory developments; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 10, 2022, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Company Contact:
IN8bio, Inc.
Patrick McCall

+ 1 646.600.6GDT (6438)

info@IN8bio.com

Investors & Media Contact:

Argot Partners

IN8bio@argotpartners.com